Abstract
Introduction Allergic rhinitis (AR) has been reported to affect between 20% and 40% of the world population. Oralair ® obtained indication for the treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive skin test and/or a positive titre of specific grass pollen IgE. The French Health Technology Assessment agency requested to set up a post-authorisation cohort study to describe Oralair ® real-world treatment pattern and patients characteristics. Methods Patients with an initiation of Oralair ® before pollen season in 2015, were included in a cohort study and followed by allergy specialists to the end of the pollen season. Results 90 allergy specialists included 280 adults and 203 children, with a mean age of 33.8 years and 11.8 years at inclusion, 49.6% men and 63.5% boys, age of onset of AR = 15.2 (±10.2) and 4.0 (±2.9) years, 87.1% and 83.7% with conjunctivitis, 41.4% and 34.3% had asthma, 87.9% and 85.2% of AR classified as persistent during the year before, 98.6% and 92.6% as moderate-severe (ARIA classification). A skin test was performed for all patients. Oralair ® was started 3–5 months before pollen season for 85.1% and continued during pollen season for most patients, with a mean duration of 2.5 months. Treatment was discontinued early ( Conclusion This study shows that the conditions of Oralair ® prescriptions by allergy specialists followed the indication recommendations well, and were associated with an improvement of AR severity observed for more than 3 patients out of 5, with a resolution of main previous AR symptoms for about half of the patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call